DSGN is the ticker symbol for Design Therapeutics, Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks DSGN with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is DSGN a good stock to buy?

DSGN is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/DSGN.

Where does 13F Pro source DSGN data?

All Design Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Design Therapeutics, Inc. files with the SEC under CIK 1807120. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Design Therapeutics, Inc.(DSGN)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Design Therapeutics, Inc. (DSGN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. DSGN is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Design Therapeutics, Inc. reports net income of $-20.2M, free cash flow of $-15.5M. Top institutional holders of DSGN by reported 13-F value include SR ONE CAPITAL MANAGEMENT, Logos Global Management, BAKER BROS. ADVISORS, based on the most recent SEC filings. DSGN trades on the Nasdaq exchange and files with the SEC under CIK 1807120. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DSGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Design Therapeutics, Inc. directly from SEC EDGAR.

Revenue

$0.00

Net Income

$-20.2M

Free Cash Flow

$-15.5M

DSGN key financials by period

Design Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2020	10-K	$226.0K	$-8.3M	—

Institutions holding DSGN

Institutional investors reporting a position in Design Therapeutics, Inc. on SEC Form 13F.
Institution	Shares	Value	Reported
SR ONE CAPITAL MANAGEMENT	6,526,476	$94.4M	2026-06-30
Logos Global Management	3,000,000	$43.4M	2026-06-30
BAKER BROS. ADVISORS	2,678,430	$38.8M	2026-06-30
DRIEHAUS CAPITAL MANAGEMENT	2,661,115	$38.5M	2026-06-30
BlackRock	2,660,024	$38.5M	2026-06-30
Point72 Asset Management, L.P.	2,366,453	$34.2M	2026-06-30
Trails Edge Capital Partners	2,001,282	$29.0M	2026-06-30
Frazier Life Sciences Management, L.P.	1,809,854	$26.2M	2026-06-30
Vivo Capital	1,612,903	$23.3M	2026-06-30
VANGUARD CAPITAL MANAGEMENT	1,571,022	$22.7M	2026-06-30

SEC EDGAR: CIK 1807120 →

Design Therapeutics, Inc.

DSGN

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.